BCM
SAGE

Bayesian Capital Management’s Sage Therapeutics SAGE Stock Holding History

Bayesian Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-41,425
Closed -$898K – 1079
2023
Q4 		$898K Buy
+41,425
New +$821K 0.1% 256
2022
Q4 		– Sell
-6,800
Closed -$266K – 1004
2022
Q3 		$266K Buy
+6,800
New +$263K 0.05% 450
2019
Q4 		– Sell
-1,827
Closed -$256K – 728
2019
Q3 		$256K Buy
+1,827
New +$306K 0.05% 398
2019
Q1 		– Sell
-2,290
Closed -$219K – 726
2018
Q4 		$219K Buy
+2,290
New +$262K 0.04% 496
2017
Q4 		– Sell
-4,492
Closed -$280K – 698
2017
Q3 		$280K Buy
+4,492
New +$353K 0.07% 379

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bayesian Capital Management's SAGE Position: Q1 2024 in Review

Bayesian Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2024, closing a stake of 41,425 shares — an estimated $898K sold.

Bayesian Capital Management first reported a position in SAGE in Q3 2017 and held it in 5 quarters. The position peaked at $898K in Q4 2023. 205 funds tracked by Wall St. Rank hold SAGE as of Q1 2024.

  • Bayesian Capital Management reported no remaining Sage Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 41,425 Sage Therapeutics shares in Q1 2024, an estimated $898K.
  • Bayesian Capital Management first reported a position in Sage Therapeutics in Q3 2017 and held it in 5 quarters.
  • Bayesian Capital Management's Sage Therapeutics position peaked at $898K in Q4 2023.
  • 205 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2024.

Based on Bayesian Capital Management's 13F filing for Q1 2024, filed 15 May 2024.